Granexin is under clinical development by Xequel Bio and currently in Phase III for Radiodermatitis. According to GlobalData, Phase III drugs for Radiodermatitis does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Granexin LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Granexin overview
Granexin Gel (ACT1) is under development for the treatment of pressure ulcers, cutaneous radiation injury and radiation dermatitis. The drug candidate is administered through topical route in the form of gel. It is being developed using connexin technology platform.
The drug candidate was under development for the treatment of diabetic foot ulcers, thermal burns, reducing scar formation, venous leg ulcers, post-surgical keloid scar and scar formation in surgical wounds following bilateral anchor incision breast surgery.
Xequel Bio overview
Xequel Bio is a clinical-stage biopharmaceutical company advancing its proprietary aCT1 (alpha-connexin carboxyl-terminal 1 peptide) technology platform to develop drugs. The company product pipeline includes granexin gel, inexin ophthalmic solution and aerosolized aCT1. Xequel Bio offers products in therapeutic areas such as dermatology, ophthalmology and pulmonology. It carries out aCT1 peptide technology platform to indicate inflammation and the body’s response to injury. The company has operations across the US. Xequel Bio is headquartered in Fort Worth, Texas, the US.
For a complete picture of Granexin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
